Mesoblast Limited (ASX:MSB) Head of Business Development and Licensing, David Oxley, presents details about the company's Phase 3 trials, its agreement with Tasly China and the near-term potential of stem cell medicines at FNN's Investor Event.
Key points: - Disruptive cellular medicine technology
- Investment objective and strategy
- Phase 3 trial in patients with Advanced Heart Failure
- Acute Graft Versus Host Disease
- Strategic partnership for cardiovascular franchise in China
- Key portfolio metrics
- Capital management
- Corporare milestones
For more, watch Head of Business Development and Licensing, David Oxley, present
